Track topics on Twitter Track topics that are important to you
Just a few months ago, larotrectinib was approved for treating any NTRK+ tumor. Already, there are studies in place to address any mutations that emerge with the first-generation TRK-targeted agent.
Medscape Medical News
Original Article: Getting Ready for Resistance to First-Gen NTRK InhibitorsNEXT ARTICLE